Study of Lenvatinib in Combination With Everolimus in Participants With Unresectable Advanced or Metastatic Renal Cell Carcinoma (RCC)

MLN0128 and MLN0128 + MLN1117 Compared With Everolimus in the Treatment of Adults With Advanced or Metastatic Clear-Cell Renal Cell Carcinoma

NCT02724020 ·Status: COMPLETED ·Phase: PHASE2

A Study of Belzutifan (MK-6482) as Monotherapy and in Combination With Lenvatinib (E7080/MK-7902) With or Without Pembrolizumab (MK-3475) in China Participants With Advanced Renal Cell Carcinoma (MK-6482-010)

NCT05030506 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE1

Pembrolizumab Plus Lenvatinib for First-line Advanced/Metastatic Non-clear Cell Renal Cell Carcinoma (1L nccRCC) (MK-3475-B61)

NCT04704219 ·Status: COMPLETED ·Phase: PHASE2

Biomarkers Before and After Nephrectomy of Locally Advanced or Metastatic Renal Cell Carcinoma Treated With Everolimus

NCT01715935 ·Status: COMPLETED ·Phase: PHASE2

Study of the Combination of CM082 With Everolimus in Patients With mRCC

NCT02577458 ·Status: UNKNOWN ·Phase: PHASE1

Cardenilimab Combined With Lenvatinib in Patients With Perioperative Resectable Clear Cell Renal Cell Carcinoma.

NCT06574412 ·Status: NOT_YET_RECRUITING ·Phase: PHASE2

A Trial of Everolimis in Patients With Advanced Renal Cell Carcinoma.

NCT01206764 ·Status: COMPLETED ·Phase: PHASE4

A Study of Belzutifan (MK-6482) in Combination With Lenvatinib Versus Cabozantinib for Treatment of Renal Cell Carcinoma (MK-6482-011)

NCT04586231 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE3

A Study of Pembrolizumab (MK-3475) in Combination With Belzutifan (MK-6482) and Lenvatinib (MK-7902), or Pembrolizumab/Quavonlimab (MK-1308A) in Combination With Lenvatinib, vs Pembrolizumab and Lenvatinib, for Treatment of Advanced Clear Cell Renal Cell Carcinoma (MK-6482-012)-China Extension Study

NCT05899049 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE3

Anlotinib Plus Everolimus as First-line Treatment for Advanced Non Clear Cell Renal Cell Carcinoma

NCT05124431 ·Status: UNKNOWN ·Phase: PHASE2

Dose-Finding, Safety and Efficacy Study of RX-0201 Plus Everolimus in Metastatic Renal Cell Cancer

NCT02089334 ·Status: TERMINATED ·Phase: PHASE1/PHASE2

A Study of QL1706 Plus Lenvatinib in Subjects With Advanced Renal Cell Carcinoma(RCC)

NCT05262413 ·Status: UNKNOWN ·Phase: PHASE1/PHASE2

Safety and Efficacy of Everolimus in Metastatic Renal Cell Carcinoma After Failure of First Line Therapy With Sunitinib or Pazopanib

NCT01514448 ·Status: COMPLETED ·Phase: PHASE4

A Comparison of Vorolanib Tablets Combined With Everolimus Versus Sunitinib in Patients With Advanced Renal Cell Carcinoma Who Have Progressed After Treatment With Immunotherapy Monotherapy or in Combination With TKI

NCT07165418 ·Status: NOT_YET_RECRUITING ·Phase: PHASE3

Akt Inhibitor MK2206 or Everolimus in Treating Patients With Refractory Kidney Cancer

NCT01239342 ·Status: TERMINATED ·Phase: PHASE2

Everolimus as Second-line Therapy in Metastatic Renal Cell Carcinoma

NCT01491672 ·Status: COMPLETED ·Phase: PHASE2

Study of Lenalidomide in Combination With Sunitinib to Evaluate the Safety and Efficacy in Patients With Renal Cell Carcinoma

NCT00975806 ·Status: TERMINATED ·Phase: PHASE1/PHASE2

Study of HS-10516 Combination Therapy in Patients With Advanced Renal Cell Carcinoma

NCT07097935 ·Status: RECRUITING ·Phase: PHASE1/PHASE2

Everolimus/Sorafenib or Sunitinib in Patients With Metastatic Renal Cell Carcinoma (RCC)

NCT01616186 ·Status: WITHDRAWN ·Phase: PHASE2

Panobinostat and Everolimus in Treating Patients With Metastatic or Unresectable Renal Cell Cancer That Does Not Respond to Treatment With Sunitinib Malate or Sorafenib Tosylate

NCT01582009 ·Status: TERMINATED ·Phase: PHASE1/PHASE2

Phase Ib/II Trial of Envafolimab Plus Lenvatinib for Subjects With Solid Tumors

NCT05024214 ·Status: RECRUITING ·Phase: PHASE1/PHASE2

CM082 Combined With Everolimus in Chinese Patients With Metastatic Renal Cell Carcinoma

NCT03095040 ·Status: UNKNOWN ·Phase: PHASE3

Efficacy Study of Sunitinib and Everolimus (Rotational vs Sequential Arm) in Pats. With m Clear Cell Renal Cancer

NCT01784978 ·Status: TERMINATED ·Phase: PHASE2

Open Label, Single Arm Trial to Characterize Patients With Metastatic RCC Treated With Everolimus After Failure of the First VEGF-targeted Therapy (MARC-2)

NCT01266837 ·Status: COMPLETED ·Phase: PHASE4

A Study of Pembrolizumab (MK-3475) in Combination With Belzutifan (MK-6482) and Lenvatinib (MK-7902), or Pembrolizumab/Quavonlimab (MK-1308A) in Combination With Lenvatinib, Versus Pembrolizumab and Lenvatinib, for Treatment of Advanced Clear Cell Renal Cell Carcinoma (MK-6482-012)

NCT04736706 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE3